{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"12.5","value":"0.99"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"2.2","value":"0.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"TTR is defined from JCARH125 infusion to the first document of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).\n\nsCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level plus urine M-protein level \\< 100 mg/24 h; PR=≥ 50% reduction of serum M protein plus reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg/24 h.\n\nProgressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants with sCR, CR, VGPR, or PR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"Form date of first infusion to the date of disease progression, or death, due to any reason (Up to approximately 61 months)","title":"Time to Response (TTR) in Phase 2 and Phase 2a","type":"SECONDARY","unitOfMeasure":"Months"}